       Document 0466
 DOCN  M9630466
 TI    Prospective clinical trial of high-purity factor VIII preparations in
       haemophiliacs.
 DT    9603
 AU    Varon D; National Hemophilia Center, Chaim Sheba Medical Center,;
       Tel-Hashomer, Israel.
 SO    Blood Coagul Fibrinolysis. 1995 Jul;6 Suppl 2:S82-3. Unique Identifier :
       AIDSLINE MED/96076205
 AB    An assessment of the immune status of both HIV-positive and HIV-negative
       haemophiliacs showed hypo-responsive and anergic patients in both
       groups. In HIV-positive patients, the immune suppression, in addition to
       HIV itself, may be caused by other viral infections such as all types of
       hepatitis as well as by factor VIII concentrates. The introduction of
       new technologies for preparing factor VIII concentrates led to the
       question of whether higher purity is associated with a protective effect
       on the immune system, which might improve the clinical course of
       HIV-positive patients. Factor VIII from two manufacturing processes was
       investigated, one prepared using an ion-exchange S/D step, and the other
       utilizing a monoclonal antibody step. It is concluded that changing the
       product, from the monoclonal antibody to the ion-exchange and vice versa
       in the HIV-negative patients does not cause a change in the immune
       profiles.
 DE    Chromatography, Ion Exchange  Factor VIII/*ISOLATION & PURIF/THERAPEUTIC
       USE  Follow-Up Studies  Hemophilia/*IMMUNOLOGY  Human  *HIV
       Seronegativity  *HIV Seropositivity  Prospective Studies  CLINICAL TRIAL
       CONTROLLED CLINICAL TRIAL  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

